I-Tech AB (ITECH) Q3 2026 Earnings Report

The call was predominantly positive, with strong Q3 growth, higher profitability, a 60% gross margin, rising cash, favorable shipping-market indicators, and progress in product and market expansion. The main challenges were the uncertain EU re-registration of Selektope, elevated raw material prices, customer-driven revenue volatility, regulatory costs, and the early commercialization stage of the aquaculture technologies.

Management said its target is to keep gross margin at a higher level, with “±2 percentage points” reasonable around the reported 60%; it also targets “more than double-digit growth,” expects staff costs of approximately SEK 5.5 million as a quarterly run rate, and forecasts “a continuously prudent increase of our cost expenditure.” Internal product developments are expected “within, you could say, the coming one to two years,” the biological derived additive “within the coming years,” potentially “two to three years,” while Titanium Technology is “too soon to say”; for the EOGRT study, the company hopes to have “a starting time and a CRO in place within this year,” and a possible EU non-renewal would likely come into force “within this year” with a 180-day grace period.